Ethicon

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ethicon sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).

38 total trials 4 currently recruiting 26 completed later-stage tilt top decile by trial count

Ethicon: 38 sponsored US clinical trials, 4 recruiting.

Ethicon sponsors 38 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 26 completed. 12 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stress Urinary Incontinence, with 3 trials.

Top-decile sponsor footprint

Ethicon ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

26 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

38 total, page 1 of 1

RECRUITING NA

A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery

NCT06664788

RECRUITING

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

NCT04829175

RECRUITING

GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study

NCT04829058

RECRUITING

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

NCT04829357

ACTIVE NOT RECRUITING

Post-Market Clinical Follow-Up onTVT EXACT® Continence System

NCT04829994

TERMINATED NA

POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

NCT05299606

TERMINATED

NOLA (NeuWave Observational Liver Ablation) Registry

NCT04107766

COMPLETED

Post-Market Clinical Follow-Up of STRATAFIX™ Spiral PDS™ PLUS

NCT03937011

TERMINATED NA

Ablation Confirmation Study

NCT03753789

COMPLETED

A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy

NCT03896061

TERMINATED NA

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

NCT03603652

COMPLETED Phase 3

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

NCT03255174

COMPLETED Phase 3

The EVICEL® Neurosurgery Phase III Study

NCT02457546

COMPLETED Phase 3

The Fibrin Pad CV Phase III Study

NCT02040428

COMPLETED Phase 3

The EVARREST® Fibrin Sealant Patch Liver Study

NCT01993888

COMPLETED Phase 4

EVARREST™ Fibrin Sealant Patch Post-Market Study

NCT01902459

TERMINATED Phase 1

Occipital Nerve Stimulation in the Treatment of Migraine

NCT01855672

COMPLETED Phase 2

The Fibrin Pad Cardiovascular Study

NCT01681030

COMPLETED Phase 2

The EVICEL® Gastrointestinal Study

NCT01589822

COMPLETED

Flexible Composite Next Generation Tissue Separating Mesh in Laparoscopic Incisional/Ventral Hernia Repair

NCT01162564

COMPLETED

The Evicel Post-Authorization Surveillance Study

NCT01158261

COMPLETED Phase 2

The Fibrin Patch Soft Tissue Study

NCT00658723

COMPLETED

International Hernia Mesh Registry

NCT00622583

COMPLETED Phase 2

Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

NCT00547638

COMPLETED

GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse

NCT00521066

TERMINATED NA

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080

COMPLETED

TVT Worldwide Registry

NCT00453739

TERMINATED NA

SEMPERFLO* Pain Management System in Inguinal Hernia Repair

NCT00423241

COMPLETED NA

Uretal Flow Assessment During Gynecological Procedures

NCT00453882

COMPLETED

TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

NCT00463554

COMPLETED Phase 3

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

NCT00307515

COMPLETED Phase 4

Hemostatic Matrix in Endoscopic Sinus Surgery

NCT00242437

COMPLETED Phase 3

Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

NCT00154141

COMPLETED Phase 3

A Study Comparing Topical Skin Adhesive or Sutures for Closure Due to Episiotomy or Perineal Tears Following Childbirth

NCT00196508

COMPLETED NA

A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)

NCT00196521

COMPLETED Phase 4

A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers

NCT00235209

COMPLETED Phase 3

A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery

NCT00196534

COMPLETED Phase 4

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

NCT00235196

Where Ethicon enrollment is open (later-stage tilt)

4 recruiting of 38 indexed (11% open); 26 completed (68%).

Phase mix: 12 late (III/IV) vs 5 early (I/II) (later-stage heavy).

Top condition: Stress Urinary Incontinence (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ethicon: open-pipeline peers nationwide

Peers matched on 38 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Ethicon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 152025303540 0%5%10%15% Total trials Recruiting share EthiconAcerta PharmaAstex PharmaceuticalsCorewell Health WestDePuy OrthopaedicsBastyr UniversityRowan UniversitySaint John's Cancer InstituteSun Pharmaceutical Industries Limited
Ethicon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ethicon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 38 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Ethicon page

38 registered trials is a research-attention snapshot, not an endorsement of Ethicon or any single study.

  • 4 of Ethicon's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Stress Urinary Incontinence is the condition Ethicon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stress Urinary Incontinence trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ethicon pipeline card: 38 registered trials from official public datasets.Report a data error.